AbCellera Biologics has delivered 96% year-over-year revenue growth and beaten EPS estimates in 3 of the last 4 quarters, but the thesis hinges on whether the current cash burn — negative free cash flow at roughly 144% of revenue — narrows fast enough to allow quality metrics to recover; until it does, the stock remains speculative despite a favorable long-term risk/reward geometry.
Thesis pillars
- Industry Leading Revenue Growth→Stable
- Earnings Beat Consistency→Stable
- Negative Fcf Quality Ceiling→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 24, 2026
AbCellera Biologics Inc. (ABCL) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $12.83: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 13%; Below-average business quality.
AbCellera Biologics is a clinical-stage biotechnology company developing antibody medicines, with two internal candidates in clinical trials - ABCL635 for vasomotor symptoms and ABCL575 for atopic dermatitis - alongside a portfolio of royalty and milestone stakes from more than... Read more
Sell if holding. Engine safety override at $12.83: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 13%; Below-average business quality. Chart setup: RSI 50 mid-range, Bollinger mid-band. Score 5.1/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About AbCellera Biologics Inc.
About AbCellera Biologics Inc.
AbCellera Biologics, based in Vancouver, Canada, has two antibody drug candidates in clinical trials: ABCL635, a Phase 1/2 non-hormonal treatment for menopausal vasomotor symptoms with topline data expected in the third quarter of 2026, and ABCL575, a Phase 1 treatment for atopic dermatitis with data anticipated in the fourth quarter of 2026. The company held approximately $700 million in available liquidity as of December 31, 2025, following a $146.4 million net loss for the year.
Historically, AbCellera generated revenue by acting as a technology partner: since 2014 it started 104 partner-initiated antibody discovery programs, retaining downstream royalties and milestone payments as its partners advance drugs toward approval, with 19 molecules from its platform having reached the clinic. Since late 2023 the company has shifted focus toward its own internal pipeline, reducing new discovery partnerships while continuing obligations under existing multi-year agreements. In 2025 it completed a 130,000-square-foot clinical manufacturing facility in Vancouver, allowing it to control supply chain and manufacture drug substance in-house rather than relying on a contract manufacturing organization for early-phase trials. The company has also received CAD $475.6 million (US$347.9 million) in non-dilutive government financing from Canada and British Columbia since 2020, including CAD $300 million tied to an eight-year project supporting up to 17 internal programs through Phase 1 trials.
Show full overview
AbCellera's near-term investment case turns substantially on two early-stage binary readouts rather than diversified revenue: topline Phase 1/2 data for ABCL635 is expected in the third quarter of 2026 and Phase 1 data for ABCL575 in the fourth quarter, with two additional candidates, ABCL688 and ABCL386, not entering clinical trials until 2027. The 10-K notes the company does not anticipate generating sufficient revenue to achieve profitability until it either develops a drug independently or secures significant economic participation in a partner's approved product, leaving profitability contingent on outcomes still years away.
See also: Healthcare · Biotechnology
From AbCellera Biologics Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-28Recent Developments — AbCellera Biologics Inc.
Latest news
- NEWS UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18 — benzinga Oct 12, 2026 positive
- NEWS AbCellera Presents Phase 1/2 Data On ABCL635 At TMS 2026 Annual Meeting — benzinga Oct 8, 2026 positive
- NEWS JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17 — benzinga Sep 29, 2026 positive
- NEWS Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target — benzinga Sep 24, 2026 neutral
- NEWS What'sGoing On With AbCellera Biologics Stock On Tuesday? — benzinga Aug 25, 2026 neutral
Generated 2026-10-28T11:58:43Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-06-05Item 5.02LOWBoard appointed Victor Sandor as a new independent director effective June 1, 2026, serving until the next annual shareholder meeting. Routine board appointment; no departure or successor context involved.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Unprofitable operations — net margin -248.8%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $12.83: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: High short interest: 13%; Below-average business quality. Chart setup: RSI 50 mid-range, Bollinger mid-band. Prior stop was $11.93. Score 5.1/10, moderate confidence.
Analyst target: $14.63 (+14.0% upside). Prior stop was $11.93. Stop-loss: $11.93.
Quality below floor (2.1 < 4.0); Value-trap signals (3/5): Revenue declining (-90.6% YoY), Margin compression (op margin -567.2%), Negative free cash flow.
AbCellera Biologics Inc. trades at a P/E of N/A (forward -16.8). TrendMatrix value score: 6.0/10. Verdict: Sell.
17 analysts cover ABCL with a consensus score of 4.1/5. Average price target: $17.
What does AbCellera Biologics Inc. do?AbCellera Biologics is a clinical-stage biotechnology company developing antibody medicines, with two internal...
AbCellera Biologics is a clinical-stage biotechnology company developing antibody medicines, with two internal candidates in clinical trials - ABCL635 for vasomotor symptoms and ABCL575 for atopic dermatitis - alongside a portfolio of royalty and milestone stakes from more than 100 historical partner-initiated programs. The company reported a $146.4 million net loss in 2025 against approximately $700 million in available liquidity, and has shifted its business model from a discovery-services partner to a company building its own drug pipeline.